Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study
Top-line results from the Phase IIIb LIBERTY study are positive regarding primary and secondary endpoints, and could put erenumab ahead of other CGRP antagonists in difficult-to-treat migraine, as this novel class of agents nears the market for migraine prevention.
You may also be interested in...
Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.